Disruptive mood dysregulation disorder: does variance in treatment responses also add to the conundrum? The widening gap in the evidence is a signal needing attention
- 18 November 2021
- journal article
- editorial
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 27 (6), 659-661
- https://doi.org/10.1017/s1092852921000985
Abstract
The new diagnosis of disruptive mood dysregulation disorder (DMDD) was introduced in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, to address the overdiagnosis of bipolar disorder in children and adolescents. However, there are ongoing debates about its nosology given chronic persistent irritability in children and adolescents has contextual valence. Those meeting the criteria for DMDD may, in fact, have an oppositional defiant disorder, attention deficit hyperactivity disorder, or other behavioral disorders. Similarly, in the last few years, there are many different types of treatment studies that have also yielded mixed results. These counterintuitive findings need a meticulous review for a wider debate given its clinical utility for patients, families, and practicing clinicians.Keywords
This publication has 17 references indexed in Scilit:
- White Matter Microstructure in Pediatric Bipolar Disorder and Disruptive Mood Dysregulation DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2020
- Editorial: Antidepressants to the Rescue in Severe Mood Dysregulation and Disruptive Mood Dysregulation Disorder?Journal of the American Academy of Child & Adolescent Psychiatry, 2019
- A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe IrritabilityJournal of the American Academy of Child & Adolescent Psychiatry, 2019
- Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label StudyJournal of Child and Adolescent Psychopharmacology, 2018
- Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation DisorderJournal of Child and Adolescent Psychopharmacology, 2018
- Interpersonal psychotherapy for mood and behavior dysregulation: Pilot randomized trialDepression and Anxiety, 2018
- Identifying Clinically Significant Irritability in Early ChildhoodJournal of the American Academy of Child & Adolescent Psychiatry, 2018
- Atypical antipsychotics for disruptive behaviour disorders in children and youthsEmergencias, 2017
- An empirically based alternative to DSM-5's disruptive mood dysregulation disorder for ICD-11World Psychiatry, 2015
- Role of Naltrexone in Management of Behavioral Outbursts in an Adolescent Male Diagnosed with Disruptive Mood Dysregulation DisorderJournal of Child and Adolescent Psychopharmacology, 2014